Drug General Information (ID: DDIIXQVPWJ)
  Drug Name Paclitaxel (protein-bound) Drug Info Smallpox (Vaccinia) Vaccine, Live Drug Info
  Drug Type Small molecule Vaccine
  Therapeutic Class Antineoplastics/Mitotic Inhibitors Vaccine

 Mechanism of Paclitaxel (protein-bound)-Smallpox (Vaccinia) Vaccine, Live Interaction (Severity Level: Major)
     Antagonize the effect of vaccine/toxoid Click to Show/Hide Mechanism Graph
Could Not Find 2D Structure
      Drug Name Paclitaxel (protein-bound) Smallpox (Vaccinia) Vaccine, Live
      Mechanism Immunosuppressive effects Vaccine or toxoid
      Key Mechanism Factor 1
Factor Name Vaccine/toxoid
Factor Description The beneficial effects of the vaccine/toxinoid may be reduced, leading to a diminished or suboptimal immune response.
      Mechanism Description
  • Antagonize the effect of Smallpox (Vaccinia) Vaccine, Live when combined with Paclitaxel (protein-bound) 

Recommended Action
      Management Routine, nonemergency smallpox vaccination is contraindicated in patients receiving immunosuppressive therapy or cancer chemotherapy. Vaccination should be deferred until after such therapy is discontinued for at least 3 months in most cases. A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide).

References
1 CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18. [PMID: 20300058]
2 Cerner Multum, Inc. "Australian Product Information.".
3 Product Information. Dryvax (smallpox vaccine). Wyeth-Ayerst Laboratories, Philadelphia, PA.